Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$27,000.00

Characterizing oncolysis of second-generation reovirus mutants among breast cancer models

FY 2024-25

Summary
There is a need for research into cancer therapeutics to develop new treatments and improve upon existing ones; non-pathogenic reovirus has been shown to kill cancer cells. Despite having a great safety profile in humans, the efficacy of using reovirus as a therapeutic needs to be improved. Our lab found that a metastatic breast tumor cell line was less susceptible to reovirus infection since it cannot attach to breast tumor cells as they lack a cell-surface protein that interacts with a protein on reovirus, o1. When this surface protein was put on tumor cells, the cells became susceptible to reovirus infection suggesting the lower reovirus infection is due to low levels of that protein. My Aim 1 is to establish the amount of the cell surface protein needed for reovirus infection both in tumors and cell culture. I hypothesize that there is a minimum threshold level of JAM-A needed for reovirus infection. Determining the minimum threshold of this cell protein that is needed for effective reovirus infection allows us to screen for patients where reovirus treatment will be viable as their tumors will have sufficient levels. Mutants of reovirus with altered o1 proteins were found to bind breast tumor cell so Aim 2 is to investigate how these mutations allow for binding and entry in breast tumor cells. We hypothesize is due to enhanced binding capacity to alternative binding factors on the breast tumor cells. If we can identify the mutations which would allow for efficient reovirus binding to JAM-A deficient cells, then we can modify the reovirus used for oncolytic therapies to overcome the barriers to successful treatment of tumors with low JAM-A levels. The findings from this research project may aid in engineering reovirus to be a better cancer therapeutic.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530155
Name
Luong Spencer T
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing oncolysis of second-generation reovirus mutants among breast cancer models
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cancer Therapy; Clinical; Microbiology; Molecular Biology; Oncology; Oncolytic; Reovirus; Therapeutic; Virology
Abstract
There is a need for research into cancer therapeutics to develop new treatments and improve upon existing ones; non-pathogenic reovirus has been shown to kill cancer cells. Despite having a great safety profile in humans, the efficacy of using reovirus as a therapeutic needs to be improved. Our lab found that a metastatic breast tumor cell line was less susceptible to reovirus infection since it cannot attach to breast tumor cells as they lack a cell-surface protein that interacts with a protein on reovirus, o1. When this surface protein was put on tumor cells, the cells became susceptible to reovirus infection suggesting the lower reovirus infection is due to low levels of that protein. My Aim 1 is to establish the amount of the cell surface protein needed for reovirus infection both in tumors and cell culture. I hypothesize that there is a minimum threshold level of JAM-A needed for reovirus infection. Determining the minimum threshold of this cell protein that is needed for effective reovirus infection allows us to screen for patients where reovirus treatment will be viable as their tumors will have sufficient levels. Mutants of reovirus with altered o1 proteins were found to bind breast tumor cell so Aim 2 is to investigate how these mutations allow for binding and entry in breast tumor cells. We hypothesize is due to enhanced binding capacity to alternative binding factors on the breast tumor cells. If we can identify the mutations which would allow for efficient reovirus binding to JAM-A deficient cells, then we can modify the reovirus used for oncolytic therapies to overcome the barriers to successful treatment of tumors with low JAM-A levels. The findings from this research project may aid in engineering reovirus to be a better cancer therapeutic.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Luong, Spencer T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~